$183 Million

Arcutis Biotherapeutics, Inc.

Initial Public Offering

Bookrunner, January 2020

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company’s current portfolio is comprised of topical treatments with significant potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details